Naoyuki Katayama
- Immunology top 2%
- Hematology top 0.5%
- Molecular Biology top 10%
- Oncology top 5%
- Epidemiology top 5%
- Co-authors
- Hiroshi ShikuMasahiro MasuyaKohshi OhishiKei SuzukiHideo WadaKazuhiro NishiiKazunori NakaseMakio Ogawa
- Topics
- Acute Myeloid Leukemia Research (27 papers)Immune Cell Function and Interaction (24 papers)Lymphoma Diagnosis and Treatment (24 papers)
- Journals
- Journal of Clinical OncologySHILAP Revista de lepidopterologíaBlood
- Partner nations
- JapanUnited StatesFrance
In The Last Decade
Naoyuki Katayama
226 papers receiving 3.8k citations
Peers
Comparison fields: 5 of 123
- Immunology 1.2k
- Hematology 1.1k
- Molecular Biology 823
- Oncology 795
- Epidemiology 503
Countries citing papers authored by Naoyuki Katayama
This map shows the geographic impact of Naoyuki Katayama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naoyuki Katayama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naoyuki Katayama more than expected).
Fields of papers citing papers by Naoyuki Katayama
This network shows the impact of papers produced by Naoyuki Katayama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naoyuki Katayama. The network helps show where Naoyuki Katayama may publish in the future.
Co-authorship network of co-authors of Naoyuki Katayama
This figure shows the co-authorship network connecting the top 25 collaborators of Naoyuki Katayama. A scholar is included among the top collaborators of Naoyuki Katayama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naoyuki Katayama. Naoyuki Katayama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 2 | |
| 3 | 10 | |
| 4 | 1 | |
| 5 | 21 | |
| 6 | 45 | |
| 7 | 1 | |
| 8 | 1 | |
| 9 | 54 | |
| 10 | 1 | |
| 11 | 35 | |
| 12 | 2 | |
| 13 | 21 | |
| 14 | 43 | |
| 15 | 95 | |
| 16 | 84 | |
| 17 | 13 | |
| 18 | 2 | |
| 19 | [Nasal lymphoma of natural killer cell origin]. | 4 |
| 20 | 胃がん術後１２年目に発症したｍｉｃｒｏａｎｇｉｏｐａｔｈｉｃ ｈｅｍｏｌｙｔｉｃ ａｎｅｍｉａ（ＭＨＡ）・Ｄｉｓｓｅｍｉｎａｔｅｄ ｉｎｔｒａｖａｓｃｕｌａｒ ｃｏａｇｕｌａｔｉｏｎ（ＤＩＣ）併発骨髄がんしゅ症 | 2 |
About Naoyuki Katayama
Naoyuki Katayama is a scholar working on Hematology, Internal Medicine and Immunology, having authored 246 papers that have together received 3.9k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (27 papers), Immune Cell Function and Interaction (24 papers) and Lymphoma Diagnosis and Treatment (24 papers). The work is most often cited by research in Hematology (1.1k citations), Immunology (1.2k citations) and Internal Medicine (181 citations). Naoyuki Katayama has collaborated with scholars based in Japan, United States and France. Frequent co-authors include Hiroshi Shiku, Masahiro Masuya, Kohshi Ohishi, Kei Suzuki, Hideo Wada, Kazuhiro Nishii, Kazunori Nakase, Makio Ogawa, Takeshi Matsumoto and Nobuyuki Minami. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.